Benign Mesothelioma (Solitary Fibrous Tumor)

Benign mesothelioma — more accurately called solitary fibrous tumor (SFT) of the pleura — is a rare neoplasm that, despite its historical name, is not a true mesothelioma. This critical distinction causes frequent confusion among patients and even clinicians. The term "benign mesothelioma" is a misnomer rooted in an era before modern immunohistochemistry and molecular pathology could distinguish cell origins.¹

Unlike malignant pleural mesothelioma, which arises from mesothelial cells lining the pleural cavity and grows as a diffuse sheet, solitary fibrous tumors originate from submesothelial fibroblastic cells. They are characterized by a NAB2-STAT6 gene fusion — a molecular signature entirely absent in true mesothelioma. Critically, SFTs have no established association with asbestos exposure, distinguishing them fundamentally from the malignant disease they are historically named after.²

Most SFTs are benign and curable with complete surgical resection. They typically present as well-circumscribed, often pedunculated masses attached to the visceral pleura by a stalk. However, approximately 10-15% of SFTs exhibit malignant features — including increased mitotic activity, nuclear atypia, tumor necrosis, and infiltrative borders — that predict aggressive behavior and potential recurrence after surgery.³

The practical importance of this distinction extends beyond medicine into law. Because SFTs are not caused by asbestos, a diagnosis of "benign mesothelioma" does not qualify for asbestos-related compensation. Patients who receive this diagnosis should seek pathological confirmation to ensure they do not have early or atypical malignant mesothelioma, which would have entirely different legal and treatment implications.⁴

Classification of Solitary Fibrous Tumors

• Benign SFT — well-circumscribed, low cellularity, <4 mitoses per 10 high-power fields; cured by complete resection in most cases
• Malignant SFT — high cellularity, ≥4 mitoses per 10 HPF, nuclear atypia, necrosis, or infiltrative margins; 10-15% of cases; risk of recurrence and metastasis
• Dedifferentiated SFT — rare; abrupt transition from typical SFT to high-grade sarcoma; aggressive behavior

Many SFTs are asymptomatic and discovered incidentally on chest imaging. When symptoms occur, they may include:¹

• Cough — from bronchial compression by the mass
• Chest pain — usually dull and localized
• Dyspnea — if the tumor is large enough to compress lung tissue
• Doege-Potter syndrome — hypoglycemia caused by tumor secretion of insulin-like growth factor II (IGF-II); occurs in ~5% of large SFTs
• Hypertrophic pulmonary osteoarthropathy — joint pain and finger clubbing; occurs in 10-20% of cases

Both Doege-Potter syndrome and osteoarthropathy typically resolve completely after tumor resection.

The cause of solitary fibrous tumors is a specific genetic event:²

• NAB2-STAT6 gene fusion — present in >90% of SFTs; this fusion drives tumor growth and is the defining molecular feature
• No asbestos link — unlike malignant mesothelioma, SFTs have no established association with asbestos or any other environmental exposure
• No known risk factors — SFTs appear to arise spontaneously; no occupational, environmental, or hereditary risk factors have been identified

• Chest CT/MRI — reveals a well-circumscribed, often pedunculated pleural mass; distinguishable from diffuse mesothelioma
• CT-guided biopsy or surgical excision — tissue sampling for histological evaluation
• STAT6 nuclear immunostaining — the gold-standard diagnostic marker; positive in >95% of SFTs, negative in mesothelioma
• Additional IHC markers — CD34 (+), Bcl-2 (+), CD99 (+); calretinin (-), WT-1 (-) — ruling out true mesothelioma
• Molecular testing — NAB2-STAT6 fusion confirmation by FISH or sequencing

• Complete surgical resection — the standard and usually curative treatment; includes the tumor with adequate margins
• Video-assisted thoracoscopic surgery (VATS) — preferred for smaller, pedunculated tumors
• Open thoracotomy — required for large or sessile tumors
• Radiation therapy — considered for incompletely resected or recurrent malignant SFTs
• Systemic therapy — anti-angiogenic agents (pazopanib, bevacizumab + temozolomide) for unresectable or metastatic malignant SFTs
• Long-term surveillance — serial imaging recommended even after complete resection due to risk of late recurrence (reported up to 20 years later)

The prognosis for benign SFTs is excellent, with cure rates exceeding 90% after complete surgical resection. Malignant SFTs have a more guarded prognosis, with 10-year recurrence rates of approximately 30-40% and potential for distant metastases (lung, liver, bone). The Demicco risk stratification model uses tumor size, mitotic count, and patient age to predict recurrence risk.³

After SFT resection, patients require long-term follow-up with periodic chest imaging (CT scans), as recurrences can develop years or even decades after initial surgery. Patients should be reassured that this diagnosis is distinct from malignant mesothelioma and does not indicate asbestos exposure.⁴